blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2513146

EP2513146 - ANTIBODIES AGAINST ROR1 CAPABLE OF INDUCING CELL DEATH OF CLL [Right-click to bookmark this link]
Former [2012/43]BIOLOGICAL INHIBITORS OF ROR1 CAPABLE OF INDUCING CELL DEATH
[2016/48]
StatusPatent revoked
Status updated on  21.02.2020
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  31.03.2017
FormerGrant of patent is intended
Status updated on  23.11.2016
Most recent event   Tooltip27.05.2022Lapse of the patent in a contracting state
New state(s): TR		published on 29.06.2022  [2022/26]
Applicant(s)For all designated states
Kancera AB
Karolinska Science Park
Banvaktsvägen 22
171 48 Solna / SE
[2015/11]
Former [2012/43]For all designated states
BioInvent International AB
Sölvegatan 41
223 70 Lund / SE
Inventor(s)01 / MELLSTEDT, Håkan
Nybrogatan 45 B
Stockholm 114 39 / SE
02 / RABBANI, Hodjattallah
Midskeppsgatan 1
5 tr
120 79 Stockholm / SE
03 / TEIGE, Ingrid
Raketgatan 6
244 57 Lund / SE
 [2017/18]
Former [2012/43]01 / MELLSTEDT, Håkan
Nybrogatan 45 B
Stockholm 114 39 / SE
02 / RABBANI, Hodjattallah
Midskeppsgatan 1
5 tr
S-120 79 Stockholm / SE
03 / TEIGE, Ingrid
Raketgatan 6
S-244 57 Lund / SE
Representative(s)Novitas Patent AB
P.O. Box 55557
102 04 Stockholm / SE
[2017/18]
Former [2012/43]Höglund, Lars, et al
Albihns.Zacco AB
P.O. Box 5581
114 85 Stockholm / SE
Application number, filing date10798728.110.12.2010
[2017/18]
WO2010EP07524
Priority number, dateGB2010000930703.06.2010         Original published format: GB 201009307
GB2009002214318.12.2009         Original published format: GB 0922143
[2012/43]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011079902
Date:07.07.2011
Language:EN
[2011/27]
Type: A2 Application without search report 
No.:EP2513146
Date:24.10.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 07.07.2011 takes the place of the publication of the European patent application.
[2012/43]
Type: B1 Patent specification 
No.:EP2513146
Date:03.05.2017
Language:EN
[2017/18]
Search report(s)International search report - published on:EP29.09.2011
ClassificationIPC:C07K16/28
[2012/43]
CPC:
C07K16/2803 (EP,US); C07K16/28 (US); C12N15/1137 (EP,US);
C12N15/1138 (US); A61K2039/505 (EP,US); C07K2317/34 (EP,US);
C07K2317/73 (EP,US); C07K2317/732 (EP,US); C12N2310/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/43]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTIKÖRPER GEGEN ROR1, DIE CLL ZELLTOD VERURSACHEN[2016/48]
English:ANTIBODIES AGAINST ROR1 CAPABLE OF INDUCING CELL DEATH OF CLL[2016/48]
French:ANTICORPS CONTRE ROR1 INDUISANT LA MORT CELLULAIRE DE CELLULES CLL[2016/48]
Former [2012/43]ZELLTOD INDUZIERENDE BIOLOGISCHE ROR1-HEMMER
Former [2012/43]BIOLOGICAL INHIBITORS OF ROR1 CAPABLE OF INDUCING CELL DEATH
Former [2012/43]MATÉRIAUX BIOLOGIQUES ET UTILISATIONS DE CEUX-CI
Entry into regional phase04.07.2012National basic fee paid 
04.07.2012Designation fee(s) paid 
04.07.2012Examination fee paid 
Examination procedure04.07.2012Examination requested  [2012/43]
23.01.2013Amendment by applicant (claims and/or description)
15.12.2015Despatch of a communication from the examining division (Time limit: M06)
14.06.2016Reply to a communication from the examining division
24.11.2016Communication of intention to grant the patent
22.03.2017Fee for grant paid
22.03.2017Fee for publishing/printing paid
22.03.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.12.2015
Opposition(s)Opponent(s)01  05.02.2018  12.02.2018  ADMISSIBLE
Bischof, Oliver
Bischof & Partner Rechtsanwälte
Partnerschaftsgesellschaft mbB
An den Speichern 6
48157 Münster / DE
 02  05.02.2018  12.02.2018  ADMISSIBLE
Taylor, David
Ablett & Stebbing
7-8 Market Place
London Greater London W1W 8AG / GB
Opponent's representative
Lewis Silkin LLP
Arbor
255 Blackfriars Road
London SE1 9AX / GB
 [N/P]
Former [2019/40]
Opponent(s)01  05.02.2018  12.02.2018  ADMISSIBLE
Bischof, Oliver
Bischof & Partner Rechtsanwälte
Partnerschaftsgesellschaft mbB
An den Speichern 6
48157 Münster / DE
 02  05.02.2018  12.02.2018  ADMISSIBLE
Taylor, David
Ablett & Stebbing
7-8 Market Place
London Greater London W1W 8AG / GB
Opponent's representative
Lewis Silkin LLP
5 Chancery Lane
Clifford's Inn
London EC4A 1BL / GB
Former [2018/11]
Opponent(s)01  05.02.2018    ADMISSIBLE
Bischof, Oliver
Bischof & Partner Rechtsanwälte
Partnerschaftsgesellschaft mbB
An den Speichern 6
48157 Münster / DE
 02  05.02.2018   
Taylor, David
Ablett & Stebbing
7-8 Market Place
London Greater London W1W 8AG / GB
Opponent's representative
Taylor, David Matthew Joseph, et al, et al
Ablett & Stebbing
7-8 Market Place
London Greater London W1W 8AG / GB
15.02.2018Invitation to proprietor to file observations on the notice of opposition
24.08.2018Reply of patent proprietor to notice(s) of opposition
07.11.2019Despatch of communication that the patent will be revoked
17.11.2019Legal effect of revocation of patent [2020/13]
Fees paidRenewal fee
13.12.2012Renewal fee patent year 03
12.12.2013Renewal fee patent year 04
11.12.2014Renewal fee patent year 05
08.12.2015Renewal fee patent year 06
22.12.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.12.2010
AL03.05.2017
AT03.05.2017
CY03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
MK03.05.2017
PL03.05.2017
PT03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
TR03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
[2022/26]
Former [2020/33]HU10.12.2010
AL03.05.2017
AT03.05.2017
CY03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
MK03.05.2017
PL03.05.2017
PT03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2020/22]HU10.12.2010
AT03.05.2017
CY03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
MK03.05.2017
PL03.05.2017
PT03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2019/52]HU10.12.2010
AT03.05.2017
CY03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
MK03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2019/46]HU10.12.2010
AT03.05.2017
CY03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2019/31]HU10.12.2010
AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2019/30]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
MC03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2018/45]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
IE10.12.2017
LU10.12.2017
MT10.12.2017
Former [2018/43]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
LU10.12.2017
MT10.12.2017
Former [2018/25]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SI03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Former [2018/11]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SK03.05.2017
SM03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Former [2018/10]AT03.05.2017
CZ03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RO03.05.2017
RS03.05.2017
SK03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Former [2018/09]AT03.05.2017
EE03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RS03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Former [2017/50]AT03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
LV03.05.2017
PL03.05.2017
RS03.05.2017
BG03.08.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Former [2017/49]AT03.05.2017
FI03.05.2017
HR03.05.2017
LT03.05.2017
NO03.08.2017
GR04.08.2017
IS03.09.2017
Cited inInternational search[XI]WO2005100605  (UNIV CALIFORNIA [US], et al) [X] 1-7,13-31 * the whole document * [I] 8-12;
 [XI]WO2007146957  (IRM LLC [BM], et al) [X] 8-11 * the whole document * [I] 1-7,12-31;
 [XA]WO2008076868  (ABBOTT LAB [US], et al) [X] 1-7,13-31 * the whole document * [A] 8-12;
 [XP]WO2010124188  (US HEALTH [US], et al) [XP] 1-31 * the whole document *;
 [XA]  - AMIR H DANESHMANESH ET AL, "Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 123, no. 5, doi:DOI:10.1002/IJC.23587, ISSN 0020-7136, (20080901), pages 1190 - 1195, (20080610), XP002622341 [X] 1-7,27 * the whole document * [A] 8-26,28-31

DOI:   http://dx.doi.org/10.1002/ijc.23587
 [I]  - BASKAR SIVASUBRAMANIAN ET AL, "Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20080115), vol. 14, no. 2, doi:DOI:10.1158/1078-0432.CCR-07-1823, ISSN 1078-0432, pages 396 - 404, XP009135221 [I] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-1823
 [A]  - LAPALOMBELLA ROSA ET AL, "Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 115, no. 13, doi:DOI:10.1182/BLOOD-2009-09-242438, ISSN 0006-4971, (20091124), pages 2619 - 2629, (20091124), XP009146859 [A] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood-2009-09-242438
 [A]  - FUKUDA TETSUYA ET AL, "Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 105, no. 8, doi:DOI:10.1073/PNAS.0712148105, ISSN 0027-8424, (20080226), pages 3047 - 3052, (20080219), XP009135222 [A] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.0712148105
 [X]  - MACKEIGAN JEFFREY P ET AL, "Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance", NATURE CELL BIOLOGY, NATURE PUBLISHING GROUP, GB, (20050601), vol. 7, no. 6, doi:DOI:10.1038/NCB1258, ISSN 1465-7392, pages 591 - 600, XP002425115 [X] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.1038/ncb1258
 [XP]  - ANIRUDDHA CHOUDHURY ET AL, "Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 151, no. 4, doi:DOI:10.1111/J.1365-2141.2010.08362.X, ISSN 0007-1048, (20100831), pages 327 - 335, (20100831), XP002622344 [XP] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2010.08362.x
 [X]  - J. W. TYNER ET AL, "RNAi screen for rapid therapeutic target identification in leukemia patients", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20090526), vol. 106, no. 21, doi:10.1073/pnas.0903233106, ISSN 0027-8424, pages 8695 - 8700, XP055003694 [X] 1-31 * the whole document * * including supporting information *

DOI:   http://dx.doi.org/10.1073/pnas.0903233106
 [A]  - TAKAYAMA K ET AL, "Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, (20000415), vol. 60, no. 8, ISSN 0008-5472, pages 2169 - 2177, XP002312417 [A] 1-31 * the whole document *
 [A]  - HEANEY D L ET AL, "SOLUBLE RECEPTORS IN HUMAN DISEASE", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, (19980801), vol. 64, no. 2, ISSN 0741-5400, pages 135 - 146, XP008005930 [A] 1-31 * the whole document *
Examination   - DANESHMANESH A H ET AL, Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells., LEUKEMIA JUN 2012, VOL. 26, NR. 6, PAGE(S) 1348 - 1355, (201206), ISSN 1476-5551
by applicantUS4440859
 US4530901
 US4582800
 US4677063
 US4678751
 US4704362
 US4710463
 US4757006
 US4766075
 US4810648
 WO9816643
    - CHIORAZZI N ET AL., N ENGL J MED, (2005), vol. 352, pages 804 - 15
    - DAMLE RN ET AL., BLOOD, (1999), vol. 94, pages 1840 - 7
    - HAMBLIN TJ ET AL., BLOOD, (1999), vol. 94, pages 1848 - 54
    - KLEIN U ET AL., J EXP MED, (2001), vol. 194, pages 1625 - 38
    - ROSENWALD A ET AL., J EXP MED, (2001), vol. 194, pages 1639 - 47
    - GLASS DJ ET AL., CELL, (1996), vol. 85, pages 513 - 23
    - MASIAKOWSKI P ET AL., J BIOL CHEM, (1992), vol. 267, pages 26181 - 90
    - VALENZUELA DM ET AL., NEURON, (1995), vol. 15, pages 573 - 84
    - MASIAKOWSKI P ET AL., BIOL CHEM, (1992), vol. 267, pages 26181 - 90
    - YODA A ET AL., J RECEPT SIGNAL TRANSDUCT RES, (2003), vol. 23, pages 1 - 15
    - REDDY UR ET AL., ONCOGENE, (1996), vol. 13, pages 1555 - 9
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - BETTER ET AL., SCIENCE, (1988), vol. 240, page 1041
    - SKERRA ET AL., SCIENCE, (1988), vol. 240, page 1038
    - BIRD ET AL., SCIENCE, (1988), vol. 242, page 423
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 5879
    - WARD ET AL., NATURE, (1989), vol. 341, page 544
    - WINTER ET AL., NATURE, (1991), vol. 349, pages 293 - 299
    - D. WILKINSON, The Scientist, THE SCIENTIST, INC., (20000417), vol. 14, pages 25 - 28
    - MCCAFFREYA. P., MEUSEL., PHAMT. T., CONKLIND. S., HANNON, G. J.KAY, M. A., "RNA interference in adult mice", NATURE, (2002), vol. 418, pages 38 - 39
    - SONGE., LEES. K., WANQ, J. ET AL., NAT. MED., (2003), vol. 9, pages 347 - 351
    - SAIKI ET AL., SCIENCE, (1988), vol. 239, pages 487 - 491
    - KOHLERMILSTEIN C, NATURE, (1975), vol. 256, pages 495 - 7
    - HARRIS NL ET AL., HISTOPATHOLOGY, (2000), vol. 36, pages 69 - 86
    - CHESON B ET AL., BLOOD, (1996), vol. 87, pages 4990 - 4997
    - REZVANY MR ET AL., BR J HAEMATOL, (2000), vol. 111, pages 608 - 17
    - MIKAELSSON E ET AL., BLOOD, (2005), vol. 105, pages 4828 - 35
    - MIKAELSSON ET AL., BLOOD, (2005), vol. 105, page 4828
    - KOKHAEI P ET AL., EXP HEMATOL, (2007), vol. 35, pages 297 - 304
    - WILLEMS P ET AL., "Belgium-Dutch Hematology-Oncology Group", BLOOD, (2000), vol. 96, pages 63 - 70
    - KOKHAEI ET AL., EXP HEMATOL, (2007), vol. 35, page 297
    - HAY H, J CLIN LAB IMMUNOL, (1989), vol. 29, pages 151 - 5
    - REZVANY MR ET AL., BR J HAEMATOL, (2001), vol. 115, pages 263 - 71
    - DEROSSI ET AL., TRENDS CELL BIOL., (1998), vol. 8, pages 84 - 87
OppositionWO2005100605
 WO2007051077
 WO2008076868
 WO2008103849
 WO2010124188
 US2013273073
    - FUKODA et al., "Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a", PNAS, (20080226), vol. 105, no. 8, pages 3047 - 3052, XP009135222

DOI:   http://dx.doi.org/10.1073/pnas.0712148105
    - BASKAR et al., "Targeting malignant B cells with an immunotoxin against ROR1", mAbs, (20120500), vol. 4, no. 3, pages 349 - 361, XP002710758

DOI:   http://dx.doi.org/10.4161/MABS.19870
    - UniProtKB, (20171220), Database accession no. Q01973, XP055468014
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.